Literature DB >> 28751833

ANMCO/ISS/AMD/ANCE/ARCA/FADOI/GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/SID/SIF/SIMEU/SIMG/SIMI/SISA Joint Consensus Document on cholesterol and cardiovascular risk: diagnostic-therapeutic pathway in Italy.

Michele Massimo Gulizia1,2, Furio Colivicchi1, Gualtiero Ricciardi3, Simona Giampaoli3, Aldo Pietro Maggioni4, Maurizio Averna5, Maria Stella Graziani6, Ferruccio Ceriotti6, Alessandro Mugelli7, Francesco Rossi7, Gerardo Medea8, Damiano Parretti8, Maurizio Giuseppe Abrignani1, Marcello Arca5, Pasquale Perrone Filardi9, Francesco Perticone10, Alberico Catapano5, Raffaele Griffo11, Federico Nardi1, Carmine Riccio1, Andrea Di Lenarda1, Marino Scherillo1, Nicoletta Musacchio12, Antonio Vittorio Panno13, Giovanni Battista Zito14, Mauro Campanini15, Leonardo Bolognese16, Pompilio Massimo Faggiano17, Giuseppe Musumeci17, Enrico Pusineri18, Marcello Ciaccio6, Enzo Bonora19, Giorgio Cantelli Forti7, Maria Pia Ruggieri20, Claudio Cricelli8, Francesco Romeo9, Roberto Ferrari9, Attilio Maseri21.   

Abstract

Atherosclerotic cardiovascular disease still represents the leading cause of death in Western countries. A wealth of scientific evidence demonstrates that increased blood cholesterol levels have a major impact on the outbreak and progression of atherosclerotic plaques. Moreover, several cholesterol-lowering pharmacological agents, including statins and ezetimibe, have proved effective in improving clinical outcomes. This document focuses on the clinical management of hypercholesterolaemia and has been conceived by 16 Italian medical associations with the support of the Italian National Institute of Health. The authors discuss in detail the role of hypercholesterolaemia in the genesis of atherosclerotic cardiovascular disease. In addition, the implications for high cholesterol levels in the definition of the individual cardiovascular risk profile have been carefully analysed, while all available therapeutic options for blood cholesterol reduction and cardiovascular risk mitigation have been explored. Finally, this document outlines the diagnostic and therapeutic pathways for the clinical management of patients with hypercholesterolaemia.

Entities:  

Keywords:  Atherosclerosis; Diagnostic and therapeutic pathways; Hypercholesterolaemia; PCSK9 inhibitors; Statins; Sustainable health care

Year:  2017        PMID: 28751833      PMCID: PMC5526476          DOI: 10.1093/eurheartj/sux029

Source DB:  PubMed          Journal:  Eur Heart J Suppl        ISSN: 1520-765X            Impact factor:   1.803


  206 in total

1.  Clofibrate and niacin in coronary heart disease.

Authors: 
Journal:  JAMA       Date:  1975-01-27       Impact factor: 56.272

Review 2.  Complexity science: complexity and clinical care.

Authors:  T Wilson; T Holt; T Greenhalgh
Journal:  BMJ       Date:  2001-09-22

3.  Complexity, leadership, and management in healthcare organisations.

Authors:  P E Plsek; T Wilson
Journal:  BMJ       Date:  2001-09-29

4.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).

Authors: 
Journal:  JAMA       Date:  2001-05-16       Impact factor: 56.272

5.  Diabetes duration and cause-specific mortality in the Verona Diabetes Study.

Authors:  E Brun; R G Nelson; P H Bennett; G Imperatore; G Zoppini; G Verlato; M Muggeo
Journal:  Diabetes Care       Date:  2000-08       Impact factor: 19.112

6.  Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.

Authors:  H B Rubins; S J Robins; D Collins; C L Fye; J W Anderson; M B Elam; F H Faas; E Linares; E J Schaefer; G Schectman; T J Wilt; J Wittes
Journal:  N Engl J Med       Date:  1999-08-05       Impact factor: 91.245

7.  Elevated serum triglyceride levels and long-term mortality in patients with coronary heart disease: the Bezafibrate Infarction Prevention (BIP) Registry.

Authors:  M Haim; M Benderly; D Brunner; S Behar; E Graff; H Reicher-Reiss; U Goldbourt
Journal:  Circulation       Date:  1999-08-03       Impact factor: 29.690

8.  A clinimetric evaluation of specialized geriatric care for rural dwelling, frail older people.

Authors:  K Rockwood; K Stadnyk; D Carver; K M MacPherson; H E Beanlands; C Powell; P Stolee; V S Thomas; R S Tonks
Journal:  J Am Geriatr Soc       Date:  2000-09       Impact factor: 5.562

9.  A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits.

Authors:  H Okamoto; F Yonemori; K Wakitani; T Minowa; K Maeda; H Shinkai
Journal:  Nature       Date:  2000-07-13       Impact factor: 49.962

10.  Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico.

Authors: 
Journal:  Lancet       Date:  1999-08-07       Impact factor: 79.321

View more
  2 in total

Review 1.  Recent Updates and Advances in the Use of Glycated Albumin for the Diagnosis and Monitoring of Diabetes and Renal, Cerebro- and Cardio-Metabolic Diseases.

Authors:  Rosaria Vincenza Giglio; Bruna Lo Sasso; Luisa Agnello; Giulia Bivona; Rosanna Maniscalco; Daniela Ligi; Ferdinando Mannello; Marcello Ciaccio
Journal:  J Clin Med       Date:  2020-11-11       Impact factor: 4.241

Review 2.  Novel Therapeutical Approaches to Managing Atherosclerotic Risk.

Authors:  Rosaria Vincenza Giglio; Anca Pantea Stoian; Khalid Al-Rasadi; Maciej Banach; Angelo Maria Patti; Marcello Ciaccio; Ali A Rizvi; Manfredi Rizzo
Journal:  Int J Mol Sci       Date:  2021-04-28       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.